Literature DB >> 12452870

Use of the Self-Administered Eczema Area and Severity Index by parent caregivers: results of a validation study.

T S Housman1, M J Patel, F Camacho, S R Feldman, A B Fleischer, R Balkrishnan.   

Abstract

BACKGROUND: The Eczema Area and Severity Index (EASI) is used by dermatological investigators world-wide to assess eczema disease severity. EASI measures are, however, time-consuming and require trained personnel, thereby limiting its application to large-scale epidemiological studies. Additionally, the use of self-assessed severity indices in dermatology is restricted to adult subjects and conditions, thereby not addressing the needs of paediatric patients.
OBJECTIVES: To develop and validate an instrument for a caregiver's self-assessment of the severity of his/her child's atopic dermatitis (AD), the Self-Administered EASI (SA-EASI).
METHODS: Trained investigators performed a modified EASI assessment on the same day as an SA-EASI was obtained from 47 caregivers of children with AD.
RESULTS: The SA-EASI was found to be a valid measure of the severity of AD. Total, acute and chronic SA-EASI scores predicted total, acute and chronic modified EASI scores (P < 0.0001). SA-EASI body surface area (BSA) scores predicted EASI BSA scores (P < 0.0001). SA-EASI pruritus scores correlated with the acute, chronic and total EASI scores (P = 0.0001).
CONCLUSIONS: The SA-EASI may provide caregivers the means to report the severity of their child's skin disease objectively. The high correlation with the EASI score observed in this sample implies that statistical inferences with the SA-EASI will be valid for large populations. In future studies, this will permit analysis of the relationship of skin disease severity to such measures as quality of life, disability, patient satisfaction and the costs of various therapies. Moreover, this SA-EASI instrument may allow older children, over 12 years old, to assess the severity of their AD.

Entities:  

Mesh:

Year:  2002        PMID: 12452870     DOI: 10.1046/j.1365-2133.2002.05031.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  17 in total

1.  Sleep Disturbance and Sleep-Related Impairment in Adults With Atopic Dermatitis: A Cross-sectional Study.

Authors:  Jennifer C Li; Anna Fishbein; Vivek Singam; Kevin R Patel; Phyllis C Zee; Hrayr Attarian; David Cella; Jonathan I Silverberg
Journal:  Dermatitis       Date:  2018 Sep/Oct       Impact factor: 4.845

2.  Atopic dermatitis.

Authors:  Thomas Bieber
Journal:  Ann Dermatol       Date:  2010-05-17       Impact factor: 1.444

3.  The development and validation of the Family Reported Outcome Measure (FROM-16)© to assess the impact of disease on the partner or family member.

Authors:  Catherine Jane Golics; Mohammad Khurshid Azam Basra; Andrew Yule Finlay; Sam Salek
Journal:  Qual Life Res       Date:  2014-02       Impact factor: 4.147

4.  Disease severity and associated family impact in childhood atopic dermatitis.

Authors:  R Balkrishnan; T S Housman; C Carroll; S R Feldman; A B Fleischer
Journal:  Arch Dis Child       Date:  2003-05       Impact factor: 3.791

Review 5.  Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis.

Authors:  Lawrence F Eichenfield; Wynnis L Tom; Sarah L Chamlin; Steven R Feldman; Jon M Hanifin; Eric L Simpson; Timothy G Berger; James N Bergman; David E Cohen; Kevin D Cooper; Kelly M Cordoro; Dawn M Davis; Alfons Krol; David J Margolis; Amy S Paller; Kathryn Schwarzenberger; Robert A Silverman; Hywel C Williams; Craig A Elmets; Julie Block; Christopher G Harrod; Wendy Smith Begolka; Robert Sidbury
Journal:  J Am Acad Dermatol       Date:  2013-11-27       Impact factor: 11.527

Review 6.  Strategies for using topical corticosteroids in children and adults with eczema.

Authors:  Stephanie J Lax; Jane Harvey; Emma Axon; Laura Howells; Miriam Santer; Matthew J Ridd; Sandra Lawton; Sinéad Langan; Amanda Roberts; Amina Ahmed; Ingrid Muller; Long Chiau Ming; Saumya Panda; Pavel Chernyshov; Ben Carter; Hywel C Williams; Kim S Thomas; Joanne R Chalmers
Journal:  Cochrane Database Syst Rev       Date:  2022-03-11

7.  Inflammatory phenotypes underlying uncontrolled childhood asthma despite inhaled corticosteroid treatment: rationale and design of the PACMAN2 study.

Authors:  Susanne J H Vijverberg; Leo Koenderman; Francine C van Erp; Cornelis K van der Ent; Dirkje S Postma; Paul Brinkman; Peter J Sterk; Jan A M Raaijmakers; Anke-Hilse Maitland-van der Zee
Journal:  BMC Pediatr       Date:  2013-06-15       Impact factor: 2.125

8.  The expert network and electronic portal for children with respiratory and allergic symptoms: rationale and design.

Authors:  Kim Zomer-Kooijker; Francine C van Erp; Walter A F Balemans; Bart E van Ewijk; Cornelis K van der Ent
Journal:  BMC Pediatr       Date:  2013-01-16       Impact factor: 2.125

9.  Systemic treatments for eczema: a network meta-analysis.

Authors:  Ratree Sawangjit; Piyameth Dilokthornsakul; Antonia Lloyd-Lavery; Nai Ming Lai; Robert Dellavalle; Nathorn Chaiyakunapruk
Journal:  Cochrane Database Syst Rev       Date:  2020-09-14

10.  Differences in Psychometric Properties of Clinician- and Patient-Reported Outcome Measures for Atopic Dermatitis by Race and Skin Tone: A Systematic Review.

Authors:  Trisha Kaundinya; Uros Rakita; Armaan Guraya; Donna Maria Abboud; Emily Croce; Jacob P Thyssen; Andrew Alexis; Jonathan I Silverberg
Journal:  J Invest Dermatol       Date:  2021-08-02       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.